The company is stopping work on its software program called Verily Value Suite. Originally known as Google Life Sciences, the company has focused on digital health, including rolling out an online diabetes clinic and an online tool to connect research participants with studies.
In September, the company received $1 billion in funding from Alphabet.
“We are making changes that refine our strategy, prioritize our product portfolio and simplify our operating model,” Verily CEO Stephen Gillett wrote in an email to employees. “We will advance fewer initiatives with greater resources.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
